Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Griffiths

Showing results (1521-1530 of 1,887) with videos related to

Pageof 189
Sort By:
Experimental Dermatology|August 22, 2003
A Crohn's disease-associated insertion polymorphism (3020insC) in the NOD2 gene is not associated with psoriasis vulgaris, palmo-plantar pustular psoriasis or guttate psoriasisC Young, M H Allen, A Cuthbert, et al.
The British Journal of Dermatology|July 5, 2016
Motivational interviewing-based training enhances clinicians' skills and knowledge in psoriasis: findings from the Pso Well<sup>®</sup> studyA Chisholm, P A Nelson, C J Pearce, et al.
The Journal of Investigative Dermatology|July 22, 2018
A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for PsoriasisAmy C Foulkes, David S Watson, Daniel F Carr, et al.
Journal of the American Academy of Dermatology|June 20, 2015
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Kim Papp, Kristian Reich, Craig L Leonardi, et al.
The British Journal of Dermatology|January 20, 2016
Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa studyV J Ludbrook, K J Hicks, K E Hanrott, et al.
BMC Medicine|October 24, 2014
Epidemiology of multimorbidity in China and implications for the healthcare system: cross-sectional survey among 162,464 community household residents in southern ChinaHarry H X Wang, Jia Ji Wang, Samuel Y S Wong, et al.
The Journal of Pediatrics|December 13, 2000
Oral tacrolimus treatment of severe colitis in childrenA Bousvaros, B S Kirschner, S L Werlin, et al.
The American Journal of Gastroenterology|March 30, 2004
CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's diseaseBill Newman, Mark S Silverberg, Xiangjun Gu, et al.
Journal of Drugs in Dermatology : JDD|August 2, 2024
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body AreasAlice B Gottlieb, April Armstrong, Andrew Blauvelt, et al.
American Journal of Hypertension|April 18, 2013
Antihypertensive prescriptions over a 10-year period in a large Chinese populationMartin C S Wong, Wilson W S Tam, Clement S K Cheung, et al.
Pageof 189

Showing results (1521-1530 of 1,887) with videos related to

Sort By:
Pageof 189
Experimental Dermatology|August 22, 2003
A Crohn's disease-associated insertion polymorphism (3020insC) in the NOD2 gene is not associated with psoriasis vulgaris, palmo-plantar pustular psoriasis or guttate psoriasisC Young, M H Allen, A Cuthbert, et al.
The British Journal of Dermatology|July 5, 2016
Motivational interviewing-based training enhances clinicians' skills and knowledge in psoriasis: findings from the Pso Well<sup>®</sup> studyA Chisholm, P A Nelson, C J Pearce, et al.
The Journal of Investigative Dermatology|July 22, 2018
A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for PsoriasisAmy C Foulkes, David S Watson, Daniel F Carr, et al.
Journal of the American Academy of Dermatology|June 20, 2015
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Kim Papp, Kristian Reich, Craig L Leonardi, et al.
The British Journal of Dermatology|January 20, 2016
Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa studyV J Ludbrook, K J Hicks, K E Hanrott, et al.
BMC Medicine|October 24, 2014
Epidemiology of multimorbidity in China and implications for the healthcare system: cross-sectional survey among 162,464 community household residents in southern ChinaHarry H X Wang, Jia Ji Wang, Samuel Y S Wong, et al.
The Journal of Pediatrics|December 13, 2000
Oral tacrolimus treatment of severe colitis in childrenA Bousvaros, B S Kirschner, S L Werlin, et al.
The American Journal of Gastroenterology|March 30, 2004
CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's diseaseBill Newman, Mark S Silverberg, Xiangjun Gu, et al.
Journal of Drugs in Dermatology : JDD|August 2, 2024
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body AreasAlice B Gottlieb, April Armstrong, Andrew Blauvelt, et al.
American Journal of Hypertension|April 18, 2013
Antihypertensive prescriptions over a 10-year period in a large Chinese populationMartin C S Wong, Wilson W S Tam, Clement S K Cheung, et al.
Pageof 189